Accretion Nutraveda IPO GMP, issue size, price band, lot size, company background, objectives and listing outlook. A complete Accretion Nutraveda IPO review for informed investing.
Accretion Nutraveda IPO Basics : Dates, Price Band, Lot Size and Issue Structure
Key IPO Details
| Parameter | Details |
|---|---|
| IPO Open | January 28, 2026 (Wednesday) |
| IPO Close | January 30, 2026 (Friday) |
| Price Band | ₹122 – ₹129 per share |
| Face Value | ₹10 per share |
| Lot Size | 1,000 shares (minimum application: 2 lots) |
| Minimum Investment | ₹2,58,000 (2,000 shares at upper band) |
| Issue Size | ₹24.77 crore (fresh issue, 19,20,000 shares) |
| Listing Platform | BSE SME |
| Allotment Date | February 2, 2026 (Monday) |
| Refunds | February 3, 2026 (Tuesday) |
| Credit of Shares | February 3, 2026 (Tuesday) |
| Listing Date | February 4, 2026 (Wednesday) |
| Registrar | Kfin Technologies Ltd. |
| Lead Manager | Sobhagya Capital Options Pvt. Ltd. |
| Market Maker | Sunflower Broking Pvt. Ltd. |
The Accretion Nutraveda IPO is a book built issue, entirely a fresh issue with no offer for sale. The price band is set at ₹122–₹129 per share and the minimum application size is 2,000 shares (2 lots), translating to a substantial minimum investment of ₹2,58,000 for retail investors at the upper price band.
Company Background: Accretion Nutraveda’s Journey and Business Model
The Story So Far
Accretion Nutraveda Limited, incorporated in March 2021 in Ahmedabad, Gujarat, is a healthcare focused Contract Development and Manufacturing Organization (CDMO) specializing in Ayurvedic and nutraceutical products.
Business Model: CDMO and Private Label Manufacturing
Accretion Nutraveda operates primarily as a CDMO, offering end to end solutions from formulation development to manufacturing, packaging, and quality testing. The company’s product portfolio spans:
- Tablets (film-coated, chewable)
- Capsules (hard gelatin, HPMC)
- Oral liquids (syrups, suspensions, tonics)
- Powders (churans)
- Oils (Kshir Paak, medicated)
- External preparations (balms, creams, gels, ointments)
This diversity allows Accretion Nutraveda to cater to a wide range of therapeutic and wellness segments, including liver care, women’s health, bone and joint health, cognitive support, respiratory wellness, digestive care, pediatric nutrition, and skin/hair care.
The company’s revenue model is split between:
- Domestic Sales & Merchant Exports (Loan License Basis): 96.62% of FY25 revenue
- Direct Exports: 3.38%, with growing presence in Sri Lanka, Singapore, and the USA
This dual focus on domestic and international markets provides both scale and diversification, while the CDMO/private label approach enables Accretion Nutraveda to serve both large corporate clients and niche specialty brands.
Manufacturing Facility and Certifications
The company operates from a modern, GMP compliant, leased manufacturing facility in Sanand, Gujarat, spanning 10,763 sq. ft. The plant is equipped with 13 air handling units (HEPA filtration), segregated processing and dispensing areas, and in-house physico chemical, instrumental, and microbiology labs for stringent quality assurance.
Certifications include:
- WHO-GMP
- FSSC 22000
- ISO 9001:2015 (Quality Management)
- ISO 45001:2018 (Occupational Health & Safety)
- Halal certification
- FSSAI license
These certifications not only ensure compliance with Indian and international standards but also enhance the company’s credibility with global clients and regulatory authorities.
Accretion Nutraveda IPO Financials and Key Metrics:
Financial Performance Snapshot
| Period Ended | Revenue (₹ Cr) | PAT (₹ Cr) | EBITDA (₹ Cr) | Net Worth (₹ Cr) | Assets (₹ Cr) | Borrowings (₹ Cr) |
|---|---|---|---|---|---|---|
| Mar 31, 2023 | 3.07 | 0.28 | 0.59 | 0.26 | 4.06 | 1.97 |
| Mar 31, 2024 | 5.20 | 0.82 | 1.21 | 1.08 | 4.64 | 2.17 |
| Mar 31, 2025 | 16.06 | 2.61 | 3.65 | 5.35 | 10.86 | 3.86 |
| Sep 30, 2025 | 14.07* | 2.33* | 3.29* | 8.26 | 16.35 | 4.43 |
*H1 FY26 (six months).
Key Ratios and Margins
| Metric | FY23 | FY24 | FY25 | H1 FY26 |
|---|---|---|---|---|
| EBITDA Margin (%) | 20.36 | 24.10 | 22.79 | 23.36 |
| PAT Margin (%) | 9.66 | 16.40 | 16.33 | 16.59 |
| ROE (%) | 107.69 | 75.93 | 81.22 | 68.54 |
| ROCE (%) | 12.51 | 28.98 | 36.98 | 49.09 |
| Debt/Equity | 7.19 | 2.00 | 0.72 | 0.54 |
| EPS (₹) | 0.78 | 2.28 | 7.19 | 4.91 |
| Price/Earnings (P/E) | — | — | 26.27* | 20.02** |
| Price/Book Value | — | — | 8.76 | 7.71 |
*Pre-IPO, **Post-IPO.
Analysis
Accretion Nutraveda’s financials tell a story of rapid scale up. Revenue grew from ₹3.07 crore in FY23 to ₹16.06 crore in FY25 a CAGR of over 200%. Profitability has improved in tandem, with PAT margin expanding from under 10% to over 16%. The company’s return ratios are exceptionally high, though this is partly due to a small equity base; as the capital base expands post IPO, these ratios are expected to normalize.
The company’s balance sheet has strengthened, with net worth rising from ₹0.26 crore in FY23 to ₹8.26 crore by September 2025. Borrowings have increased to support growth, but the debt/equity ratio has improved, indicating prudent leverage management.
Accretion Nutraveda IPO Objectives: Where Will the Money Go?
The net proceeds from the IPO are earmarked for:
- Purchase of Machineries for Automation in Existing Manufacturing Unit: ₹4.22 crore
- Purchase of Machineries for New Manufacturing Setup: ₹8.03 crore
- Funding Working Capital Requirements: ₹5.50 crore
- General Corporate Purposes: Balance
This allocation reflects Accretion Nutraveda’s focus on scaling up operations, enhancing automation, and expanding manufacturing capacity to meet growing demand in both domestic and export markets.
Promoters, Management Team, and Shareholding
Promoters and Key Management
The company is led by a team of experienced professionals with deep roots in the pharmaceutical and nutraceutical industries:
- Mayur Popatlal Sojitra (Managing Director): B.Pharm, MBA (International Business, University of Greenwich, London); over a decade in pharma and healthcare.
- Ankurkumar Shantilal Patel (Whole-Time Director): B.Pharm, M.Pharm (Ayurved); 16+ years in pharma/nutraceuticals, R&D, and QA/QC.
- Paraskumar Vinubhai Parmar (CFO & Executive Director): B.Pharm, MA (International Business); financial management and strategic planning.
- Hardik Mukundbhai Prajapati (Non-Executive Director): B.Pharm, M.Pharm; 14+ years in pharma operations and marketing.
- Harshad Nanubhai Rathod (Non-Executive Director): B.Pharm, MBA; expertise in regulatory affairs and business development.
- Vivek Ashok Kumar Patel (Non-Executive Director): B.Pharm, MBA (Pharma Industry Management); experience in production and marketing.
The board also includes independent directors, ensuring strong corporate governance.
Shareholding Pattern
| Shareholder | Pre-IPO Holding | Post-IPO Holding |
|---|---|---|
| Promoters | 100% | 73.48% |
| Public (IPO) | 0% | 26.52% |
The promoters’ significant post issue holding demonstrates ongoing commitment and alignment with shareholder interests.
Anchor Investors and Allocation
On January 27, 2026, Accretion Nutraveda raised ₹7.02 crore from anchor investors, allocating 5,44,000 shares at ₹129 per share. The anchor investors are:
- Unicorn Fund: 4,66,000 shares (85.66% of anchor portion)
- Radiant Global Fund Class B Participating Shares: 78,000 shares (14.34% of anchor portion)
The anchor lock-in period is 30 days for 50% of shares and 90 days for the remaining 50%, providing some post listing stability.
Subscription Status and Grey Market Premium (GMP)
Subscription Trends
The IPO has seen a muted response in the first two days:
- Day 1: Subscribed only 0.01 times overall; retail 0.05x, NII 0.01x, QIB 0x.
- Day 2: Improved to 0.57x overall; QIB (ex-anchor) 0.99x, NII 0.42x, retail 0.39x.
The high minimum investment and SME segment risks may be contributing to the tepid demand, especially among retail and HNI investors.
Grey Market Premium (GMP)
As of the IPO week, the GMP for Accretion Nutraveda is ₹0 , indicating no premium or discount in the unofficial grey market. This suggests that the market expects the stock to list close to its issue price, with no immediate listing gains anticipated.
Listing Details and Timetable
| Event | Date |
|---|---|
| IPO Opens | January 28, 2026 |
| IPO Closes | January 30, 2026 |
| Allotment Finalization | February 2, 2026 |
| Refunds Initiated | February 3, 2026 |
| Shares Credited to Demat | February 3, 2026 |
| Listing Date | February 4, 2026 |
Shares will be listed on the BSE SME platform. Investors can check their allotment status on the Kfin Technologies website or BSE IPO portal after February 2, 2026.
Market Positioning and Growth Prospects
The Indian Nutraceutical and Ayurveda Market
India’s nutraceutical market is booming, driven by rising health consciousness, preventive healthcare trends, and a renewed interest in traditional wellness systems like Ayurveda. The market was valued at USD 8.93 billion in 2025 and is projected to reach USD 23.09 billion by 2034 (CAGR ~11.1%).
Key trends include:
- Personalized nutrition: Customized supplements and functional foods are gaining traction.
- Plant-based and clean-label products: Consumers prefer natural, herbal, and additive free formulations.
- Digital transformation: E commerce and D2C brands are expanding reach, especially in urban and semi urban areas.
- Regulatory support: FSSAI and government initiatives are fostering innovation and quality standards.
Major players include Dabur, Himalaya, Patanjali, Amway, Herbalife, and a growing number of startups and SMEs.
Accretion Nutraveda’s Position
Accretion Nutraveda leverages the convergence of Ayurveda and modern nutraceutical science, offering a diverse product portfolio and flexible manufacturing capabilities. Its focus on CDMO/private label manufacturing positions it as a partner of choice for both established brands and emerging wellness startups.
The company’s certifications (WHO-GMP, ISO, FSSC, Halal, FSSAI) and export orientation provide a competitive edge in both domestic and international markets. Its rapid revenue growth and improving margins reflect strong execution and market demand.
Strengths and Competitive Advantages
1. Experienced Promoters and Management:
The leadership team combines technical expertise in pharmaceuticals, Ayurveda, and nutraceuticals with business acumen and global exposure. This blend supports innovation, operational excellence and strategic growth.
2. Diverse Product Portfolio:
With over 400 formulations across multiple dosage forms and therapeutic segments, Accretion Nutraveda can cater to a wide range of client needs and market trends.
3. Commitment to Quality:
The company’s manufacturing facility is certified to global standards, ensuring product safety, efficacy and regulatory compliance. This is crucial for both domestic and export markets.
4. Established Client and Supplier Relationships:
Long standing partnerships with both large corporates and specialty brands, as well as reliable supplier networks, underpin business stability and scalability.
5. Robust Financial Growth:
The company has demonstrated rapid revenue and profit growth, with strong margins and high return ratios.
6. Geographic Diversification:
Exports to Sri Lanka, Singapore, and the USA provide access to higher margin markets and reduce dependence on any single geography.
7. Scalable Business Model:
The CDMO/private label approach allows for flexible capacity utilization and the ability to serve multiple clients across segments.
Risks and Red Flags
1. Short Operating History:
Accretion Nutraveda was incorporated in 2021, making it a relatively new entrant. While growth has been impressive, the company’s ability to sustain this trajectory remains to be proven.
2. High Minimum Investment:
The minimum application size of ₹2,58,000 may deter retail participation and limit liquidity post listing.
3. SME Segment Risks:
SME IPOs are inherently riskier, with lower liquidity, higher volatility, and less analyst coverage compared to mainboard listings.
4. Regulatory and Compliance Risks:
The Ayurvedic and nutraceutical sectors are subject to evolving regulations. Any tightening of norms or adverse regulatory actions could impact operations.
5. Customer and Supplier Concentration:
As a contract manufacturer, the company may be dependent on a few key clients or suppliers, exposing it to concentration risks.
6. Litigation:
There is an ongoing complaint regarding a batch of product found not of standard quality, which the company is contesting in court. A group company was also penalized by SEBI for disclosure lapses.
7. High Return Ratios May Normalize:
The current high ROE and ROCE are partly due to a small equity base. As capital increases post IPO, these ratios are expected to moderate.
Valuation and Peer Comparison
| Company | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) | P/E | RoNW (%) | NAV (₹) | EBITDA (%) | PAT (%) |
|---|---|---|---|---|---|---|---|---|
| Accretion Nutraveda | 14.07* | 2.33* | 4.91 | 26.27 | 56.50 | 16.74 | 23.36 | 16.59 |
| Walpar Nutritions | 28.72 | 1.00 | 1.06 | 23.94 | 6.24 | 17.05 | 4.90 | 3.48 |
| Influx Healthtech | 66.76 | 10.01 | 4.81 | 25.93 | 11.10 | 38.98 | 21.96 | 15.00 |
*As of Sep 2025.
Accretion Nutraveda’s valuation (P/E ~26x pre IPO, ~20x post-IPO) is in line with listed SME peers, though its scale is smaller. However, its margins and return ratios are superior, reflecting operational efficiency and growth potential.
Broker Recommendations and Analyst Reviews
Most brokerages and IPO analysts have adopted a may apply or neutral stance on the Accretion Nutraveda IPO. The positives includes strong growth, robust margins and a high-potential sector are balanced by concerns over the high minimum investment, SME risks and the company’s short track record.
Investors are advised to consider their risk appetite, investment horizon and portfolio allocation before applying.
How to Apply: Step by Step Guide
Eligibility:
You need a Demat account, a trading account and a bank account linked for online payments.
Application Methods:
- ASBA (Application Supported by Blocked Amount):
- Log in to your net banking portal.
- Navigate to the IPO section.
- Select – Accretion Nutraveda IPO
- Enter bid details (quantity, price).
- Confirm and submit.
- UPI through Broker Platforms:
- Log in to your broker’s app (e.g., Zerodha, Angel One, Upstox).
- Go to the IPO section.
- Select the IPO and enter bid details.
- Enter your UPI ID and approve the mandate.
Minimum Application:
- Retail: 2,000 shares (2 lots) = ₹2,58,000 at upper price band.
- S-HNI: 3,000 shares (3 lots) = ₹3,87,000.
- B-HNI: 8,000 shares (8 lots) = ₹10,32,000.
Allotment:
Check status on the Kfin Technologies website or BSE IPO portal after February 2, 2026.
Post Listing Performance and Monitoring
Investors should monitor :
- Listing price and initial trading volumes
- Post-listing price trends and liquidity
- Quarterly financial updates and order book growth
- Any regulatory or litigation developments
- Peer performance and sector trends
Given the lull subscription and zero GMP, the stock may list near its issue price. Long term performance will depend on the company’s ability to sustain growth, manage risks, and execute its expansion plans.
The Bigger Picture : India’s Nutraceutical Boom and Accretion Nutraveda’s Opportunity
India’s nutraceutical sector is at an inflection point, it is driven by following :
- Rising health awareness and preventive healthcare
- Government support for Ayurveda and wellness industries
- Growing middle class and urbanization
- Digital transformation and e-commerce expansion
- Favorable regulatory environment (FSSAI, Ayush Aahar, PLI schemes)
Accretion Nutraveda, with its modern manufacturing, quality certifications, and export orientation is well placed to capitalize on these trends. However, competition is intense, with established players like Dabur, Himalaya, Patanjali, Amway and Herbalife.
Conclusion: Should You Apply for the Accretion Nutraveda IPO?
The Accretion Nutraveda IPO offers exposure to a high growth sector with strong tailwinds. The company’s rapid financial growth, robust margins, and quality focus are attractive. However, the high minimum investment, SME segment risks, and short operating history warrant caution.
Who should consider applying?
- Investors with a high risk appetite and a long term horizon.
- Those seeking exposure to the Ayurvedic and nutraceutical manufacturing space.
- Investors comfortable with SME IPO dynamics and lower liquidity.
Who should be cautious?
- First time IPO investors or those with limited capital.
- Investors seeking quick listing gains (given zero GMP and muted subscription).
- Those uncomfortable with the risks of a young, fast-growing company.
As always, do your own research, consult your financial advisor and invest only what you can afford to lock in for the medium to long term.
Frequently Asked Questions (FAQs)
Q: What is the Accretion Nutraveda IPO GMP?
A: As of IPO week, the GMP is ₹0, indicating no premium or discount in the grey market.
Q: What are the IPO opening and closing dates?
A: Opens January 28, 2026; closes January 30, 2026.
Q: What is the minimum investment for retail investors?
A: ₹2,58,000 (2,000 shares at ₹129 per share).
Q: When will the shares be listed?
A: Tentative listing date is February 4, 2026, on BSE SME.
Q: How can I check my allotment status?
A: Visit the Kfin Technologies website or BSE IPO portal after February 2, 2026.
Q: What are the main risks?
A: Short operating history, SME segment volatility, high minimum investment, regulatory risks, and customer/supplier concentration.
Final Word
The Accretion Nutraveda IPO is a classic case of high risk, high reward. The company’s growth trajectory and sectoral tailwinds are compelling, but investors must weigh these against the risks inherent in SME IPOs and new ventures. If you’re bullish on India’s nutraceutical revolution and comfortable with the risks, this IPO could be worth a closer look.